Compare Amphastar Pharmaceuticals Inc (AMPH) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Paychex, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Paychex, Inc. trades at $121.38 (market cap $43.10B). The key difference: Paychex, Inc. is far larger — about 49.9× Amphastar Pharmaceuticals Inc's market cap, and Paychex, Inc. pays a 3.93% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | PAYX | |
|---|---|---|
Market Cap | $863.95M | $43.10B |
Sector | Health | Industrials |
52-Week High | $30.81 | $140.81 |
52-Week Low | $16.87 | $85.57 |
Enterprise Value | $1.26B | $46.59B |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Paychex (PAYX) trades at $120.04, down slightly by 0.07% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.32 exceeding the $1.31 estimate. Revenue grew to $5.57 billion in 2025, though net income margin dipped to 27.03%. Recent news highlights expansion of its WISE platform and steady small business employment trends, supporting growth prospects.
The outlook remains positive given consistent earnings outperformance and strategic initiatives, but risks include elevated valuation ratios and potential economic sensitivity. Analyst consensus is mixed with a hold-heavy rating, and the current price sits above the $114.50 target, suggesting limited near-term upside. Dividend payments provide income support, yet investors should weigh growth against premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
